In one paragraphArticle in ACS infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
James E GomezInfectious Disease and Microbiome Program, Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02142, United States.ORCID 0000-0002-2640-7453 Matthew Y SolomonInfectious Disease and Microbiome Program, Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02142, United States.
Diana K HuntInfectious Disease and Microbiome Program, Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02142, United States.
Emily J GeddesCenter for Integrated Solutions for Infectious Diseases, Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02142, United States.
Austin N BondInfectious Disease and Microbiome Program, Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02142, United States.ORCID 0009-0001-8486-0619 Cong LiuCenter for the Development of Therapeutics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02142, United States.ORCID 0000-0002-1687-2220 Rebecca J UlrichInfectious Disease and Microbiome Program, Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02142, United States.ORCID 0000-0001-6013-6565 Pooja V ChaudharyInfectious Disease and Microbiome Program, Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02142, United States.
Sulyman BarkhoCenter for Integrated Solutions for Infectious Diseases, Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02142, United States.
Deborah T HungInfectious Disease and Microbiome Program, Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02142, United States.ORCID 0000-0003-4262-0673 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
PROSPECT (PRimary screening Of Strains to Prioritize Expanded Chemistry and Targets) is an antimicrobial discovery platform based on chemical-genetic interaction profiling of compounds against a pool of
Indexed as
Antitubercular AgentsBacterial ProteinsEnzyme InhibitorsMycobacterium tuberculosisPolyketide SynthasesPyrazolesSmall Molecule LibrariesMicrobial Sensitivity TestsAntitubercular AgentsBacterial ProteinsEnzyme Inhibitorspolyketide synthase Pks13, Mycobacterium tuberculosisPolyketide SynthasesPyrazolesSmall Molecule Librarieschemical-genetic interactionM. tuberculosispolyketide synthasetarget-based phenotypic screening
Identifiers
PMID42126262
PMCPMC13271088
What Socratic holds
Textmetadata
Read underepoch 390